SHANG.FOS.PHARM.GR.H YC 1 - Asset Resilience Ratio
SHANG.FOS.PHARM.GR.H YC 1 (08HH) has an Asset Resilience Ratio of 1.81% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how SHANG.FOS.PHARM.GR.H YC 1's Asset Resilience Ratio has changed over time. See 08HH FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down SHANG.FOS.PHARM.GR.H YC 1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 08HH market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €2.23 Billion | 1.81% |
| Total Liquid Assets | €2.23 Billion | 1.81% |
Asset Resilience Insights
- Limited Liquidity: SHANG.FOS.PHARM.GR.H YC 1 maintains only 1.81% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SHANG.FOS.PHARM.GR.H YC 1 Industry Peers by Asset Resilience Ratio
Compare SHANG.FOS.PHARM.GR.H YC 1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Garden Bio-chemical High-tech Co Ltd
SHE:300401 |
Drug Manufacturers - Specialty & Generic | 5.09% |
|
KPC Pharmaceuticals Inc
SHG:600422 |
Drug Manufacturers - Specialty & Generic | 16.37% |
Annual Asset Resilience Ratio for SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for SHANG.FOS.PHARM.GR.H YC 1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.88% | €2.25 Billion ≈ $2.64 Billion |
€120.05 Billion ≈ $140.36 Billion |
-0.33pp |
| 2024-12-31 | 2.21% | €2.60 Billion ≈ $3.03 Billion |
€117.46 Billion ≈ $137.32 Billion |
+0.55pp |
| 2023-12-31 | 1.66% | €1.89 Billion ≈ $2.21 Billion |
€113.47 Billion ≈ $132.66 Billion |
+0.80pp |
| 2022-12-31 | 0.87% | €928.53 Million ≈ $1.09 Billion |
€107.16 Billion ≈ $125.29 Billion |
-3.68pp |
| 2021-12-31 | 4.55% | €4.24 Billion ≈ $4.96 Billion |
€93.31 Billion ≈ $109.08 Billion |
-- |
About SHANG.FOS.PHARM.GR.H YC 1
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumor… Read more